Ortin Global (ORTINGLOBE)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹15.8 |
| Market Cap | ₹12.85 Cr |
| P/E Ratio | 0 |
| ROCE | -25.11% |
| ROE | -46.07% |
| Dividend Yield | 0% |
| Profit Growth | -92.65% |
| Debt/Equity | 0.81 |
| Sales Growth | -80.22% |
| Promoter Holding | 1.23% |
| 52-Week Range | ₹10.66 — ₹19.92 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹1.33 |
Strengths
- Positive book value of ₹2.60 per share provides some tangible asset support.
- Debt/equity of 0.72 is not excessive, so leverage is not the immediate risk.
- Piotroski F-Score of 5/9 suggests some basic financial health signals are intact.
- Reported 61.54% profit growth may indicate losses are narrowing from a low base.
Concerns
- Sales growth is -66.67% and the latest quarter shows sales of ₹0 Cr, indicating a stalled business.
- ROE at -39.80% and ROCE at -25.11% show serious value destruction.
- P/B of 5.69 is expensive for a loss-making company with no earnings (P/E 0.00).
- Promoter holding of only 1.23% shows almost no managerial skin in the game.
AI Analysis
Let me apply the Graham test first: a company should have positive earnings, a reasonable balance sheet, and a promoter with skin in the game. Ortin Global fails all three. The latest quarter shows sales of ₹0 Cr and a net loss of ₹0 Cr, while trailing sales have collapsed by 66.67%. I don't need a calculator to see that a business with no revenue cannot compound value. The market cap is only ₹14 Cr, but the price-to-book of 5.69 means Mr. Market is asking me to pay almost six times book for a business earning -39.80% on equity and -25.11% on capital employed. That is not investing; it is speculation. Promoter holding of 1.23% is my biggest red flag. If the people running the business own almost nothing, while outsiders own the rest, I have no reason to believe my interests are aligned. Debt/equity of 0.72 is not extreme, but with negative sales and no profit, even moderate debt can become a problem. The reported 61.54% profit growth is misleading; it likely comes from a lower base of losses, not from a durable earnings stream. Piotroski F-Score of 5/9 offers a sliver of hope, but it does not overcome absent sales and poor returns. Benjamin Graham said price is what you pay, value is what you get. Here, I get negative ROE, no dividend, and almost no promoter ownership. At ₹14.79, I would rather wait. A true margin of safety appears only when this company can show real quarterly sales, positive operating cash flow, and a price closer to or below book value. Until then, this is a pass.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer